Thymosin β4 inhibits PDGF-BB induced activation, proliferation, and migration of human hepatic stellate cells via its actin-binding domain.

Shah R, Reyes-Gordillo K, Rojkind M

Expert opinion on biological therapy1 Jul 2018Cited by 10 (Europe PMC)

PMID30063851PMCIDPMC6748868DOI10.1080/14712598.2018.1478961PepBankPUB-30063851

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone13

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

01LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In human hepatic stellate cells, the Tβ4 fragment 17-23aa inhibited PDGF-BB-dependent up-regulation of PDGFβ receptor.
In plain wordsIn lab-grown human liver cells, a short piece of thymosin beta‑4 lowered a receptor that PDGF-BB raises.
Peptide
Thymosin beta-4 (human)
Outcome
DecreasePDGFβ receptor up-regulation by PDGF-BB with 17-23aa
Study
humann: not reported in source
Early passage human hepatic stellate cell cultures treated with PDGF-BB
Comparator
PDGF-BB alone
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
We showed that 17-23aa but not 1-15aa inhibited PDGF-BB-dependent up-regulation of PDGFβ receptor, α-SMA, and collagen 1.
1 context sentence(design, population, supporting numbers)
Summary · context
We used RT-PCR, Western blot, and proliferation and migration assays in early passages of human HSC cultures treated with PDGF-BB and/or Tβ4 peptides.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3006385101
02LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In human hepatic stellate cells, the Tβ4 fragment 17-23aa inhibited PDGF-BB-dependent up-regulation of α-SMA.
In plain wordsIn lab-grown human liver cells, a short piece of thymosin beta‑4 lowered a scarring marker that PDGF-BB raises.
Peptide
Thymosin beta-4 (human)
Outcome
Decreaseα-SMA up-regulation by PDGF-BB with 17-23aa
Study
humann: not reported in source
Early passage human hepatic stellate cell cultures treated with PDGF-BB
Comparator
PDGF-BB alone
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
We showed that 17-23aa but not 1-15aa inhibited PDGF-BB-dependent up-regulation of PDGFβ receptor, α-SMA, and collagen 1.
1 context sentence(design, population, supporting numbers)
Summary · context
We used RT-PCR, Western blot, and proliferation and migration assays in early passages of human HSC cultures treated with PDGF-BB and/or Tβ4 peptides.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3006385102
03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In human hepatic stellate cells, the Tβ4 fragment 17-23aa inhibited PDGF-BB-dependent up-regulation of collagen 1.
In plain wordsIn lab-grown human liver cells, a short piece of thymosin beta‑4 lowered collagen that PDGF-BB raises.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseCollagen 1 up-regulation by PDGF-BB with 17-23aa
Study
humann: not reported in source
Early passage human hepatic stellate cell cultures treated with PDGF-BB
Comparator
PDGF-BB alone
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
We showed that 17-23aa but not 1-15aa inhibited PDGF-BB-dependent up-regulation of PDGFβ receptor, α-SMA, and collagen 1.
1 context sentence(design, population, supporting numbers)
Summary · context
We used RT-PCR, Western blot, and proliferation and migration assays in early passages of human HSC cultures treated with PDGF-BB and/or Tβ4 peptides.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3006385103
04LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In human hepatic stellate cells, the Tβ4 fragment 1-15aa did not inhibit PDGF-BB-dependent up-regulation of PDGFβ receptor, α-SMA and collagen 1.
In plain wordsIn lab-grown human liver cells, a different short piece of thymosin beta‑4 did not lower these markers.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changePDGF-BB-dependent up-regulation of PDGFβ receptor, α-SMA and collagen 1 with 1-15aa
Study
humann: not reported in source
Early passage human hepatic stellate cell cultures treated with PDGF-BB
Comparator
PDGF-BB alone
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
We showed that 17-23aa but not 1-15aa inhibited PDGF-BB-dependent up-regulation of PDGFβ receptor, α-SMA, and collagen 1.
1 context sentence(design, population, supporting numbers)
Summary · context
We used RT-PCR, Western blot, and proliferation and migration assays in early passages of human HSC cultures treated with PDGF-BB and/or Tβ4 peptides.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3006385104
05LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In human hepatic stellate cells, the Tβ4 fragment 17-23aa blunted Akt phosphorylation at T308.
In plain wordsIn lab-grown human liver cells, a short piece of thymosin beta‑4 reduced activation of a growth-signal protein.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseAkt phosphorylation at T308 with 17-23aa
Study
humann: not reported in source
Early passage human hepatic stellate cell cultures treated with PDGF-BB
Comparator
PDGF-BB alone
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
It also blunted the phosphorylation of Akt at T 308 and S473, resulting in the inhibition of phosphorylation of PRAS40, and HSC proliferation and migration.
1 context sentence(design, population, supporting numbers)
Summary · context
We used RT-PCR, Western blot, and proliferation and migration assays in early passages of human HSC cultures treated with PDGF-BB and/or Tβ4 peptides.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3006385105
06LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In human hepatic stellate cells, the Tβ4 fragment 17-23aa blunted Akt phosphorylation at S473.
In plain wordsIn lab-grown human liver cells, a short piece of thymosin beta‑4 reduced activation of a growth-signal protein at a second site.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseAkt phosphorylation at S473 with 17-23aa
Study
humann: not reported in source
Early passage human hepatic stellate cell cultures treated with PDGF-BB
Comparator
PDGF-BB alone
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
It also blunted the phosphorylation of Akt at T 308 and S473, resulting in the inhibition of phosphorylation of PRAS40, and HSC proliferation and migration.
1 context sentence(design, population, supporting numbers)
Summary · context
We used RT-PCR, Western blot, and proliferation and migration assays in early passages of human HSC cultures treated with PDGF-BB and/or Tβ4 peptides.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3006385106
07LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In human hepatic stellate cells, the Tβ4 fragment 17-23aa inhibited PRAS40 phosphorylation.
In plain wordsIn lab-grown human liver cells, a short piece of thymosin beta‑4 reduced activation of the protein PRAS40.
Peptide
Thymosin beta-4 (human)
Outcome
DecreasePRAS40 phosphorylation with 17-23aa
Study
humann: not reported in source
Early passage human hepatic stellate cell cultures treated with PDGF-BB
Comparator
PDGF-BB alone
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
It also blunted the phosphorylation of Akt at T 308 and S473, resulting in the inhibition of phosphorylation of PRAS40, and HSC proliferation and migration.
1 context sentence(design, population, supporting numbers)
Summary · context
We used RT-PCR, Western blot, and proliferation and migration assays in early passages of human HSC cultures treated with PDGF-BB and/or Tβ4 peptides.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3006385107
08LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Efficacy outcome
In human hepatic stellate cells, the Tβ4 fragment 17-23aa inhibited proliferation.
In plain wordsIn lab-grown human liver cells, a short piece of thymosin beta‑4 slowed cell growth.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseHSC proliferation with 17-23aa
Study
humann: not reported in source
Early passage human hepatic stellate cell cultures treated with PDGF-BB
Comparator
PDGF-BB alone
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
It also blunted the phosphorylation of Akt at T 308 and S473, resulting in the inhibition of phosphorylation of PRAS40, and HSC proliferation and migration.
1 context sentence(design, population, supporting numbers)
Summary · context
We used RT-PCR, Western blot, and proliferation and migration assays in early passages of human HSC cultures treated with PDGF-BB and/or Tβ4 peptides.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3006385108
09LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Efficacy outcome
In human hepatic stellate cells, the Tβ4 fragment 17-23aa inhibited migration.
In plain wordsIn lab-grown human liver cells, a short piece of thymosin beta‑4 slowed cell movement.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseHSC migration with 17-23aa
Study
humann: not reported in source
Early passage human hepatic stellate cell cultures treated with PDGF-BB
Comparator
PDGF-BB alone
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
It also blunted the phosphorylation of Akt at T 308 and S473, resulting in the inhibition of phosphorylation of PRAS40, and HSC proliferation and migration.
1 context sentence(design, population, supporting numbers)
Summary · context
We used RT-PCR, Western blot, and proliferation and migration assays in early passages of human HSC cultures treated with PDGF-BB and/or Tβ4 peptides.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3006385109
10LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In human hepatic stellate cells, the Tβ4 fragment 1-15aa blocked Akt phosphorylation at S473 by inhibiting mTOR phosphorylation.
In plain wordsIn lab-grown human liver cells, a different short piece of thymosin beta‑4 blocked activation of a growth-signal protein at one site.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseAkt phosphorylation at S473 with 1-15aa
Study
humann: not reported in source
Early passage human hepatic stellate cell cultures treated with PDGF-BB
Comparator
PDGF-BB alone
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Interestingly, 1-15aa blocked Akt phosphorylation at S473, but not T308 by inhibiting mTOR phosphorylation, thus, it did not have any effect on HSC proliferation and migration.
1 context sentence(design, population, supporting numbers)
Summary · context
We used RT-PCR, Western blot, and proliferation and migration assays in early passages of human HSC cultures treated with PDGF-BB and/or Tβ4 peptides.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3006385110
11LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In human hepatic stellate cells, the Tβ4 fragment 1-15aa did not block Akt phosphorylation at T308.
In plain wordsIn lab-grown human liver cells, a different short piece of thymosin beta‑4 did not block activation of the growth-signal protein at the other site.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeAkt phosphorylation at T308 with 1-15aa
Study
humann: not reported in source
Early passage human hepatic stellate cell cultures treated with PDGF-BB
Comparator
PDGF-BB alone
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Interestingly, 1-15aa blocked Akt phosphorylation at S473, but not T308 by inhibiting mTOR phosphorylation, thus, it did not have any effect on HSC proliferation and migration.
1 context sentence(design, population, supporting numbers)
Summary · context
We used RT-PCR, Western blot, and proliferation and migration assays in early passages of human HSC cultures treated with PDGF-BB and/or Tβ4 peptides.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3006385111
12LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Efficacy outcome
In human hepatic stellate cells, the Tβ4 fragment 1-15aa had no effect on proliferation.
In plain wordsIn lab-grown human liver cells, a different short piece of thymosin beta‑4 did not change cell growth.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeHSC proliferation with 1-15aa
Study
humann: not reported in source
Early passage human hepatic stellate cell cultures treated with PDGF-BB
Comparator
PDGF-BB alone
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
thus, it did not have any effect on HSC proliferation and migration.
1 context sentence(design, population, supporting numbers)
Summary · context
We used RT-PCR, Western blot, and proliferation and migration assays in early passages of human HSC cultures treated with PDGF-BB and/or Tβ4 peptides.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3006385112
13LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Efficacy outcome
In human hepatic stellate cells, the Tβ4 fragment 1-15aa had no effect on migration.
In plain wordsIn lab-grown human liver cells, a different short piece of thymosin beta‑4 did not change cell movement.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeHSC migration with 1-15aa
Study
humann: not reported in source
Early passage human hepatic stellate cell cultures treated with PDGF-BB
Comparator
PDGF-BB alone
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
thus, it did not have any effect on HSC proliferation and migration.
1 context sentence(design, population, supporting numbers)
Summary · context
We used RT-PCR, Western blot, and proliferation and migration assays in early passages of human HSC cultures treated with PDGF-BB and/or Tβ4 peptides.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-3006385113

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.